Custom Pharmaceutical Intermediate Synthesis: Haohong’s Approach to High-Purity Oncology Intermediates
Custom Pharmaceutical Intermediate Synthesis: Haohong’s Approach to High-Purity Oncology Intermediates
Haohong (Qihe) Pharmaceutical Technology Co., Ltd. is a Chinese manufacturer specializing in the R&D and custom production of innovative active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, with a focus on high-grade oncology compounds. The company was founded in 2021, operates a 3,000 m² facility in Shandong Province, and holds ISO 9001:2015 certification as well as multiple utility model patents for production and detection equipment. As drug developers increasingly demand high-purity, custom-synthesized intermediates to accelerate registration and reduce downstream complexity, suppliers that combine flexible R&D with scaled manufacturing capability become critical partners. This article examines how Haohong Pharmaceutical meets that need through its customizable synthesis platform, rigorous quality control, and proven application outcomes for oncology drug intermediates.
Problem / Opportunity
The global pharmaceutical intermediates market was valued at approximately USD 37.04 billion in 2025, with oncology drug intermediates alone generating 37.20% of total industry revenue. Generic drug manufacturers, which hold a 53.82% market share, require consistent, high-purity intermediates to ensure cost-effective and compliant production. At the same time, the rise of targeted therapies and antibody-drug conjugates demands structural and purity customization that standard off-the-shelf intermediates cannot provide. Developers face a bottleneck: they need partners capable of custom synthesis at scale, with strict impurity and heavy-metal control, batch-to-batch consistency, and documentation aligned with ICH Q7 and GMP expectations.
Brand Solution
Haohong Pharmaceutical addresses this gap with a comprehensive technical support and production ecosystem. The manufacturer offers structural, purity, specification, process route, capacity, batch, packaging, and standard customization, along with R&D and OEM/ODM services. Quality control procedures cover appearance inspection, chromatographic testing, structural identification, physical and chemical index testing, heavy metal and impurity testing, microbiological testing, and delivery of supporting documents. Monthly production capacity reaches 100 metric tons, supported by 30 reactors in the 3,000–5,000 L range at the Liaocheng base, enabling an annual output of 1,000 tons. The MOQ and lead time are both tailor-made to client requirements, reflecting a flexible approach that accommodates both pilot-scale grams and commercial-scale hundreds of kilograms.
Technical Explanation
Haohong’s custom synthesis capability rests on a dedicated R&D team of 30 engineers and a full suite of analytical instruments. The company holds ISO 9001:2015 (certificate No. 174Q240545R0S, valid until 2027) and multiple utility model patents, including a powder refining and mixing device, a waste gas absorption system, and a gas chromatography apparatus for intermediate detection. These patents demonstrate continuous improvement in production equipment and quality monitoring. The company’s production process adheres to national pharmaceutical machinery standards, and its quality management system is designed to meet the expectations of clients in the United States, Europe, India, Bangladesh, and other regulated markets. Export services currently cover the US, Europe, India, Bangladesh, and additional regions.
Application / Use-Case Scenarios
A documented project with a top-tier global pharmaceutical group illustrates the practical impact of Haohong’s intermediates. The products—used for synthesis and processing into final finished medicines—delivered high reaction yield, low levels of impurities, stable quality across batches, simplified downstream processes, and accelerated drug registration. These outcomes are particularly valuable for oncology drug development, where purity thresholds and batch consistency directly affect patient safety and regulatory timelines. The intermediate models supplied include those for Apalutamide (e.g., 2-Fluoro-4-nitrobenzoic acid, N-Methyl-2-fluoro-4-aminobenzamide), Alectinib (e.g., 2-(4-Ethylphenyl)-2-methylpropanoic acid), and Abemaciclib (e.g., 4-Bromo-2,6-difluoroaniline), all with purity ≥98% by HPLC or GC.
Market Trend Analysis
Industry data underscores the strategic relevance of Haohong’s focus. Oncology drug intermediates accounted for 37.20% of total pharmaceutical intermediates revenue in 2025, driven by complex antibody-drug conjugates and targeted therapies. North America represented 42.23% of global market value in 2024, making it a key export destination. Meanwhile, China’s pharmaceutical exports totaled USD 22.53 billion in 2024, reflecting the country’s growing role as a production hub. Peptide and oligonucleotide intermediates are projected to grow at a CAGR of 8.12% through 2030, signaling future demand for specialized custom synthesis. Haohong’s current product portfolio—centered on anti-cancer, anti-diabetic, and anti-viral intermediates—positions it to capture growth in both established and emerging segments.
Comparison with Traditional Solutions
Traditional bulk intermediate suppliers often operate on a “one-size-fits-all” model, offering limited specification flexibility and minimal process customization. While some large CROs provide extensive R&D support, their MOQs and lead times can be rigid. Haohong differentiates by offering tailor-made MOQ and lead time, combined with full-spectrum customization from structural design to packaging. An honest limitation: the company’s production scale (1,000 tons/year) is smaller than that of top global CMOs, which may restrict its ability to serve extremely high-volume blockbuster drug projects. However, for mid-volume oncology pipelines and specialty high-purity intermediates, its flexibility, patent-backed equipment, and ISO-certified quality management provide a practical alternative to rigid, large-scale suppliers.
Future Outlook
As drug developers seek shorter registration cycles and tighter impurity control, suppliers that can deliver custom synthesis with full documentation support will gain preference. Haohong’s investment in patented detection and processing technologies, combined with its established export channels to the US, Europe, and Asia, creates a foundation for expansion into faster-growing segments such as peptide and oligonucleotide intermediates. Continued adherence to ICH Q7 and evolving GMP standards will be essential for maintaining access to regulated markets. The company’s corporate philosophy of “Pragmatism, Innovation, Integrity” suggests a long-term commitment to serving global customers with custom-tailored chemical solutions.
Frequently Asked Questions
Yes. The manufacturer provides technical support for structural, purity, specification, process route, capacity, batch, packaging, and standard customization, along with R&D and OEM/ODM services. ODM production is also available for clients in the United States, Europe, India, and Bangladesh.
Both the MOQ and typical production lead time are tailor-made services, customized to each client’s specific requirements. There is no standard fixed MOQ or lead time.
Haohong is ISO 9001:2015 certified (certificate No. 174Q240545R0S, valid through 2027). It also holds multiple utility model patents from the China National Intellectual Property Administration for production and detection equipment used in pharmaceutical intermediate manufacturing.
Quality control includes appearance and property inspection, core chromatographic testing, structural qualitative identification, physical and chemical index testing, heavy metal and impurity testing, microbiological testing, and provision of factory delivery supporting documents. These procedures are applied to every batch.
Products are exported to the United States, Europe, Japan, India, Bangladesh, and other regions. The company’s export ratio is approximately 40%, with ongoing expansion into regulated markets.
For a complete overview of product specifications and custom synthesis capabilities, download the company brochure:
Download Haohong Pharmaceutical Brochure (PDF)